More Action, Less Plan? House Keeps Pressure On US FDA Over ALS Drugs

A bipartisan letter from several key legislators is pushing the US FDA to match its actions to its rhetoric when it comes to the handling of ALS drug reviews. Amylyx’ pending AMX0035 isn’t mentioned but seems unavoidably the subject.

Congress and ALS
Congressional leaders are showing their support for ALS products • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Several key members of the House of Representatives are urging the US Food & Drug Administration to back up its public statements about “flexibility” in considering ALS therapies with some concrete actions.

House Energy & Commerce/Health Subcommittee Chair Anna Eshoo (D-CA) organized the bipartisan letter, and ranking member Brett Guthrie (R-KY)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

PS-Pathways&Standards (Free-1): Industrial Chemicals Within Us - The Ubiquity of Industrial Products in the Human Body

 
• By 

Exploring How Everyday Industrial Compounds Enter Our Systems, Their Health Implications, and the Ongoing Quest for Safer Alternatives .

Diversity Action Plans: What To Submit And When

 
• By 

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By 

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

 

The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.

More from Pathways & Standards

Anvisa To Access US FDA-Reviewed Data For More Robust Evaluations In Brazil

 

Brazil has also published its recent regulatory reliance regulations in English, a move designed to increase confidence in its decisions as it presses on with aligning its national practices with global best practices.

Califf: Rare Disease Hub Will Develop Methods To Guide Approvability Determinations

 

The US FDA commissioner also said the hub is looking for an executive director who will work with the CBER and CDER heads, who will serve as co-leads.

Primary Biliary Cholangitis Drug Confirmatory Trials Aim To Avoid Hurdles That Tripped Up Ocaliva

 
• By 

The FDA and sponsors of two new accelerated approval drugs for PBC have taken steps in study design, initiation and reporting transparency to ensure timely completion; Intercept’s COBALT trial of obeticholic acid was negatively impacted by product safety labeling changes and a high crossover rate to commercial drug.